GE HealthCare And DeepHealth Team Up To Advance AI-Powered Breast Cancer Screening: Details
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 11 2024
0mins
Source: Benzinga
Collaboration Overview: GE HealthCare Technologies Inc. has partnered with DeepHealth to enhance AI in imaging, focusing on developing SmartTechnology solutions for improved breast cancer screening and diagnostic processes.
Product Distribution and Goals: GE HealthCare will distribute DeepHealth's SmartMammo and other solutions to U.S. imaging providers, aiming for same-day diagnostic exams and better patient outcomes through rapid AI processing and clinical support.
Analyst Views on CSD
Wall Street analysts forecast CSD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSD is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 113.104
Low
Averages
High
Current: 113.104
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
